OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
ROCKVILLE, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program. The A30 RQ analyzers will now proceed into final verification and validation testing.
- The assembly of the instruments marks the successful completion of a major development milestone in the Unyvero A30 program.
- Furthermore, the Unyvero A30 RQ platform can be made available to third party development and commercialization partners and licensees for their own assay menu and product portfolio.
- The Unyvero A30 RQ platform is designed to allow straightforward migration of third party assays using well-established real time PCR technology.
- This press release includes statements regarding the development of OpGens Unyvero A30 RQ platform.